Body Protection Compound, Pentadecapeptide
A 15 amino acid synthetic peptide derived from a protein found in human gastric juice. One of the most extensively researched healing compounds in the peptide space, with over 180 PubMed publications covering tissue repair, gut healing, nerve regeneration, and cardiovascular protection.
01 — Research Summary
BPC-157 has 180+ published studies. Almost all of them are in animals. That fact is the starting point for any honest assessment of this compound.
The animal data is genuinely impressive. Severed Achilles tendons healed. Gastric ulcers resolved. Peripheral nerve damage recovered. Cardiac muscle protected after ischaemia. Brain dopamine pathways modulated. Across dozens of tissue types and injury models, BPC-157 produces consistent healing effects. The range is unusually broad for a single compound, which is explained by its mechanism — it activates multiple repair pathways simultaneously rather than targeting one receptor.
The human data is thin. Three completed trials, fewer than 30 subjects combined, no randomised placebo-controlled designs. A Phase 2 IBD trial by Pliva in Croatia confirmed safety and tolerability but results were never fully published after company restructuring. That is the sum of the controlled human evidence.
This creates an honest tension. The preclinical signal is strong enough that researchers take it seriously — over 180 papers from multiple independent labs, not just one group. But "works in rats" has a poor translation rate. Roughly 90% of drugs that show promise in animals fail in human trials. BPC-157 has not yet been tested rigorously enough in humans to know which category it falls into.
Tendon and ligament healing confirmed in animal models. Full functional restoration of severed Achilles tendons documented across multiple independent studies. The 2025 review concludes the preclinical evidence is sufficient to warrant human trials.
Consistent gastroprotection across study designs. NSAID-induced gut damage, gastric ulcers, intestinal motility disorders — all show BPC-157 benefit in animal models. The compound was literally isolated from human gastric juice, which is why gut applications have the deepest mechanistic grounding.
PCAC voted 8-6 to recommend BPC-157 for the 503A compounding list. The committee overruled FDA staff who had recommended against approval based on thin human data. Formal rulemaking now underway. Supervised compounding access possible by late 2027 if FDA accepts the recommendation.
02 — Mechanism of Action
BPC-157 stands for Body Protective Compound-157. It is a 15-amino acid peptide fragment of a protein found in human gastric juice. The body makes it. Researchers have been studying what happens when you give animals more of it since 1991.
It does not work through one target. It activates several repair pathways simultaneously, which is both why it has such broad documented effects and why pinning down the primary mechanism has taken decades.
BPC-157 upregulates VEGF and its receptor VEGFR2. New blood vessel formation is the first requirement for healing any tissue with impaired blood supply. This is the mechanism behind why it helps torn tendons specifically — tendons have poor baseline vascularity, which is why they heal slowly. BPC-157 builds the vascular infrastructure the repair process needs.
Activates endothelial nitric oxide synthase (eNOS), improving vasomotor tone and protecting vascular endothelium. The same NO pathway that cardiovascular drugs target. In gut tissue specifically, BPC-157 at the same dose as L-arginine produces comparable NO generation — which is part of why the gastroprotective effects are so consistent.
Stimulates early growth response gene 1, a transcription factor that drives the early repair cascade — cytokine production, growth factor synthesis, collagen formation. This is the upstream trigger for the healing sequence rather than a specific downstream effect, which explains the breadth of tissues that respond.
Specifically relevant to tendon healing: BPC-157 activates the FAK-paxillin pathway in tendon fibroblasts, promoting cell migration into injury sites and survival under oxidative stress. This is the most mechanistically specific data for the musculoskeletal use case.
03 — Dosing Context
No validated human dosing protocol exists. The protocols below come from the animal research scaled to human body weight, and from community-reported experience across millions of administrations. Individual responses vary. Start at the lower end.
| Route | Dose | Frequency | Duration | Primary use |
|---|---|---|---|---|
| Subcutaneous | 250–500 mcg | 1–2x daily | 4–6 weeks | Musculoskeletal, systemic |
| Intramuscular | 250–500 mcg | 1–2x daily | 4–6 weeks | Near injury site |
| Oral (PDA form) | 500 mcg | 2x daily | 8–12 weeks | Gut healing — use arginate form |
For musculoskeletal injuries, injecting near the site of damage rather than the abdomen produces stronger localised effects in animal studies. For gut healing, the oral route with the arginate salt form (PDA) is more effective than oral standard BPC-157 acetate, because the arginate form survives stomach acid better.
Independent testing has found roughly 30% of market peptide products are mislabelled, contaminated, or underdosed. This matters more for BPC-157 than most compounds because the grey market is where most people access it. A product without a current, batch-matched third-party COA is a product you cannot characterise. Do not skip this step.
04 — Community
BPC-157 is the most discussed research peptide in communities like r/Peptides by a significant margin. The volume of experience data is large enough to be genuinely informative, with the usual caveat that online forums systematically underreport negative outcomes.
The most consistent positive reports are for connective tissue injuries — tendons, ligaments — that weren't healing through conventional means. Reduced recovery time and restoration of function are the recurring themes. Gut healing reports are the second most common, typically from people with chronic gut issues including IBD, leaky gut, and NSAID-related damage.
Negative reports are uncommon relative to use volume. The most frequent problems are injection site irritation and sourcing issues — products that reconstitute incorrectly or produce no effect, suggesting contamination or underdosing.
The adverse event profile from community use is notably cleaner than from compounds with weaker animal data and similar regulatory status. Whether that reflects genuine safety or reporting bias is genuinely uncertain.